AGP Executive Report
Last update: 11 hours agoClinical Trial Update: A phase 3 STAR-221 study found domvanalimab/zimberelimab plus chemotherapy did not improve overall survival versus nivolumab plus chemotherapy for advanced HER2-negative gastroesophageal adenocarcinoma, with no clear benefit in key subgroups. Public Health Alert: Health Canada issued a recall for a banned baby walker (Vevor 4 in 1) sold in Canada, warning consumers to stop using and dispose safely due to injury risks; separate from that, Osoyoos issued a water quality advisory after manganese levels exceeded Health Canada’s maximum, advising residents to use alternate drinking water (especially for infants) and noting boiling won’t remove manganese. Healthcare Workforce: Hundreds of B.C. nurses picketed Vancouver General Hospital and expanded pickets to additional facilities, citing intimidation and pushing for labour board action. Women’s Health Research: New analysis links many ovarian cancer diagnoses to emergency admissions, with higher rates among frail, younger/older, and socioeconomically deprived patients—highlighting gaps in earlier detection. Health Policy/Access: A report on Newfoundland and Labrador argues public services are the “best deal” for household affordability and criticizes austerity, privatization, and tax cuts as ineffective for health and social outcomes. Wellness & Care Delivery: Medi Hair Loss & Scalp Clinic announced an evidence-based, non-surgical hair loss treatment expansion to Barrie for fall 2026.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
